semaglutide Archives -

Novo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which

FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovy

https://pharmaphorum.com/news/fda-ends-obesity-drug-drought/

News/ News/ R&D

Gilead pushes on with NASH partnership with Novo Nordisk

Richard Staines Genfit, Gilead, Intercept, NASH, Novo Nordisk, semaglutide 0 Comment

Gilead is one of many pharmas chasing mega-bucks promised by the fatty liver disease known as NASH –

Gilead pushes on with NASH partnership with Novo Nordisk

https://pharmaphorum.com/news/gilead-pushes-on-with-nash-partnership-with-novo-nordisk/

News/ News/ R&D

Novo Nordisk’s semaglutide effective against obesity in new trial

George Underwood Novo Nordisk, obesity, semaglutide 0 Comment

Novo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new,

Novo Nordisk’s semaglutide effective against obesity in new trial

https://pharmaphorum.com/news/novo-nordisks-semaglutide-effective-obesity-new-trial/

News/ News/ R&D

Gilead and Novo plot next steps after trial data from NASH combo

Richard Staines Gilead, hepatology, NASH, Novo Nordisk, semaglutide 0 Comment

Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked

Gilead and Novo plot next steps after trial data from NASH combo

https://pharmaphorum.com/news/gilead-and-novo-plot-next-steps-after-encouraging-data-from-nash-combo/

R&D/ Views & Analysis/ Views and analysis

Towards a new understanding of cardiovascular risk in diabetes

mike.hammerton@pharmaphorum.com cardiovascular disease, Diabetes, Novo Nordisk, semaglutide 0 Comment

A new post-hoc analysis from Novo Nordisk of their SUSTAIN 6 and PIONEER 6 studies into semaglutide is

Towards a new understanding of cardiovascular risk in diabetes

https://pharmaphorum.com/r-d/views-analysis-r-d/towards-a-new-understanding-of-cardiovascular-risk-in-diabetes/

Market Access/ News/ News

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

Phil Taylor Diabetes, metabolic diseases, Novo Nordisk, Ozempic, semaglutide 0 Comment

The FDA approval last Friday of Novo Nordisk’s Rybelsus as the first orally-active GLP-1 agonist is only the

Novo’s new oral GLP-1 Rybelsus still has obstacles to overcome

https://pharmaphorum.com/news/novos-new-oral-glp-1-still-has-obstacles-to-overcome/

News/ News/ R&D

Gilead and Novo Nordisk collaborate for NASH trial

George Underwood Gilead, NASH, Novo Nordisk, semaglutide 0 Comment

Gilead and Novo Nordisk have announced that they will collaborate on a clinical trial in nonalcoholic steatohepatitis (NASH)

Gilead and Novo Nordisk collaborate for NASH trial

https://pharmaphorum.com/news/gilead-and-novo-nordisk-collaborate-for-nash-trial/

News/ News/ R&D

Novo’s oral semaglutide on target in phase 3 trial

Richard Staines Diabetes, Eli Lilly, Novo Nordisk, Oramed, semaglutide 0 Comment

Novo Nordisk continues to build a case for its oral semaglutide GLP-1 class diabetes drug, with latest results

Novo’s oral semaglutide on target in phase 3 trial

https://pharmaphorum.com/news/novos-oral-semaglutide-target-phase-3-trial/

Diabetes/ Diabetes/ News/ News/ News/ Novo Nordisk/ Patients/ R&D/ Top pharmaceutical companies/ Top stories

Novo’s diabetes pill beats injections in head-to-head trials

Piotr Wnuk Diabetes, diabetes care, GLP-1, Insuline, Januvia, Novo Nordisk, semaglutide, Sitagliptin, Type 2 diabetes, Victoza 0 Comment

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight

Novo’s diabetes pill beats injections in head-to-head trials

https://pharmaphorum.com/news/novo-nordisks-success-with-oral-diabetes-drug/

Trending

semaglutide

Login